The Science of Microdosing
Microdosing sits at the intersection of psychopharmacology, neuroscience, and behavioral research. This page covers what the evidence actually says — mechanisms, protocols, outcomes, and the limits of what we currently know.
What Is Microdosing?
Microdosing refers to the practice of consuming sub-perceptual doses of a psychedelic substance — typically psilocybin or LSD — at regular intervals. The dose is intentionally set below the threshold for hallucinogenic effects: roughly one-tenth to one-twentieth of a full dose. At this level, most people report no perceptual distortion, no impairment of daily function, and no altered state in the traditional sense.
The practice is not new. Researchers began documenting anecdotal reports in the 1960s, and James Fadiman's 2011 work on psychedelic protocols helped formalize the concept for a modern audience. What has changed significantly in the past decade is the research infrastructure surrounding it: clinical trials at Imperial College London, Johns Hopkins University, and NYU have begun producing peer-reviewed data on mechanisms, outcomes, and safety profiles.
This page covers that research — what it shows, what it doesn't, and why the distinction matters.
"A microdose is sub-perceptual — small enough to leave ordinary functioning intact, large enough to engage the mechanisms researchers are now actively studying."
How Microdosing Works: The Mechanisms
Three primary biological pathways appear consistently in the research literature. These are not speculative — each has been observed in controlled studies and replicated across multiple research groups.
Serotonin Receptor Agonism (5-HT2A)
Psilocybin's primary mechanism involves agonism at the 5-HT2A serotonin receptor, expressed densely in the prefrontal cortex — the region governing executive function, planning, and emotional regulation. At sub-perceptual doses, this interaction appears to modulate default mode network activity without the full pattern-disruption seen at higher doses. A 2023 study in Neuropsychopharmacology found measurable 5-HT2A binding changes at doses as low as 0.1mg psilocybin.
BDNF Upregulation & Neuroplasticity
Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival and growth of neurons and the formation of new synaptic connections. Psychedelics — including at sub-perceptual doses — have been shown to upregulate BDNF expression. This is the same pathway targeted by many antidepressant compounds, and it's one reason researchers have begun examining microdosing as a potential adjunct to conventional mental health treatment. Imperial College London's 2022 psilocybin trial documented BDNF increases in participants receiving low-dose protocols.
Default Mode Network Modulation
The default mode network (DMN) is a set of brain regions active during self-referential thinking, mind-wandering, and rumination. Overactivity in the DMN is associated with depression, anxiety, and rigid thinking patterns. Neuroimaging studies show that even low doses of psilocybin reduce DMN connectivity — temporarily loosening habitual thought patterns without inducing a full psychedelic state. Carhart-Harris et al. (2016, PNAS) established this mechanism; subsequent work has extended the finding to sub-hallucinogenic doses.
What the Research Currently Shows
The research base for microdosing has expanded significantly since 2018, though it remains early relative to established pharmaceutical literature. The following represents the current state of peer-reviewed evidence.
Mood and emotional wellbeing: The largest self-report study to date — Szigeti et al. (2021, eLife), conducted by Imperial College London — followed 191 microdosers and 191 controls over four weeks. Microdosers reported small-to-medium improvements in mood, focus, and wellbeing. Critically, the study found that expectation effects (placebo) accounted for some but not all of the observed benefit.
Cognitive performance: A 2019 study by Prochazkova et al. (Psychopharmacology) found improvements in convergent and divergent thinking tasks in participants who self-administered a single microdose. The effect was observed 4 hours post-dose. Sample size was small (36 participants), and the researchers noted the absence of placebo control as a key limitation.
Depression: A 2022 randomized controlled trial by Carhart-Harris et al. (NEJM) compared psilocybin therapy to escitalopram (SSRI) in treatment-resistant depression. While this trial used full doses, not microdoses, it established the regulatory and mechanistic framework that informs current low-dose research. Several follow-on trials are now examining whether sub-perceptual dosing produces similar effects with fewer side effects.
What remains undetermined: Long-term safety profiles beyond 6 months, optimal dosing protocols across different populations, interaction effects with existing medications, and whether observed benefits persist after discontinuation.
Key references: Szigeti et al. (2021) doi:10.7554/eLife.62878 · Prochazkova et al. (2019) doi:10.1007/s00213-018-5105-2 · Carhart-Harris et al. (2022) doi:10.1056/NEJMoa2032994 · Ly et al. (2018, Cell Reports) doi:10.1016/j.celrep.2018.05.022
Protocols: What the Research Uses
The protocols studied in research settings vary in dosing frequency, dose size, and rest periods. Three appear most consistently in the literature and in structured self-report studies.
The Fadiman Protocol
James Fadiman · The Psychedelic Explorer's Guide (2011)Every third day. Designed to minimize tolerance buildup while maintaining consistent effect. The two rest days allow neurological reset. Most widely studied protocol in citizen science and academic observational research. Most referenced in self-report and observational studies.
The Stamets Stack
Paul Stamets, mycologist · ongoing trials4 days on, 3 days off. Combines psilocybin with Lion's Mane mushroom and Niacin. The addition of Lion's Mane (NGF stimulation) and Niacin (peripheral nervous system activation) is hypothesized to enhance neuroplasticity. Clinical evidence for the stack as a combination is preliminary.
Every Other Day
Used in some clinical trial designsHigher frequency than Fadiman. Some researchers prefer this for consistency of effect; others note greater tolerance risk. Suitable for closely monitored research settings. Used in several active clinical trial designs for its predictable dosing window.
The protocols described here are drawn from published research and observational studies. Evōke does not prescribe or recommend specific protocols. This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making any changes to your health regimen.
Go Deeper: Research by Topic
Each area below represents a distinct body of research. Select a topic to explore the evidence in detail.
Focus & Cognitive Performance
What research shows about attention, working memory, and creative cognition.
Read the research →Neuroplasticity
BDNF, synaptic growth, and what brain imaging studies have documented.
Read the research →Mood & Emotional Regulation
Evidence on depression, anxiety, and emotional processing outcomes.
Read the research →Protocols
Dosing schedules, tolerance windows, and what clinical trials actually use.
Read the research →Microdosing vs. Traditional Approaches
Where microdosing sits relative to SSRIs, therapy, and mindfulness research.
Read the research →Safety — What We Know
Current evidence on side effects, contraindications, and knowledge gaps.
Read the research →Evōke is designed around what the evidence shows.
The mechanisms on this page — 5-HT2A engagement, BDNF upregulation, DMN modulation — are the same ones that inform how Evōke approaches protocol design, tracking, and outcome measurement. We're building for people who want to engage with this seriously.
Learn About Evōke